Pharsight

Tekamlo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8613949 NOVARTIS Galenical formulations of organic compounds
Dec, 2029

(6 years from now)

Tekamlo is owned by Novartis.

Tekamlo contains Aliskiren Hemifumarate; Amlodipine Besylate.

Tekamlo has a total of 1 drug patent out of which 0 drug patents have expired.

Tekamlo was authorised for market use on 26 August, 2010.

Tekamlo is available in tablet;oral dosage forms.

The generics of Tekamlo are possible to be released after 21 December, 2029.

Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 26 August, 2010

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

TEKAMLO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic